Coherus Will Prioritize Oncology As Inflammation Takes A Back Seat
Sandoz Enbrel Ruling Leads Company To Chop Asset
Coherus BioSciences enjoyed another strong quarter, “exceeding expectations,” management said, as the US-based player revealed where it would invest its cash pile following a round of financing in April.
You may also be interested in...
Coherus Confident On Avastin This Year With Humira Goal Achieved
Having delivered on a goal to file its Humira biosimilar with the FDA by the end of last year, Coherus BioSciences is now focused on getting its in-licensed bevacizumab product filing over the line, as it scans the market for further growth opportunities.
Eylea Biosimilar Race Hots Up As Formycon Launches Phase III Trials
Formycon has pushed its second ophthalmology biosimilar candidate into Phase III trials, the German firm’s Eylea (aflibercept) biosimilar, FYB203, which has been licensed to Bioeq. Multiple firms are now circling Eylea, ahead of a projected US market formation in 2023.
US BioPharma Player Makes Neulasta Biosimilars Claim
The US biosimilar market for Neulasta, one of the few ‘maturing’ markets with multiple biosimilar entrants, suggests that commercial strategy more than price is of greater importance as sponsors look to prize market share from Amgen – reflecting the chasm between certain biosimilar and traditional generic markets.